Humoral Immune Response to Messenger RNA COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease

Millie Long, Michael D. Kappelman, Kimberly N. Weaver, Xian Zhang, Ann Firestine, Margie Boccieri, PREVENT-COVID Study Group
Early indicators suggest that highly effective messenger RNA (mRNA) vaccinations (BNT 162b2 [Pfizer-BioNTech] and mRNA-1273 [NIH-Moderna]) are beginning to curb the coronavirus disease 2019 (COVID-19) pandemic that has already taken the lives of 3 million individuals worldwide. However, questions about vaccine effectiveness remain for individuals with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, who are frequently treated with immune suppression. An early
more » ... tudy among transplant recipients indicated low humoral immune response after an initial vaccination, in contrast to the robust response observed in healthy individuals in phase III clinical trials. Similarly, a recent study in IBD patients suggested that treatment with infliximab is associated with an attenuated level of anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike after a single dose of mRNA vaccine.
doi:10.17615/2a83-d665 fatcat:kh7mx2wfuzgcbkfa5wc66o3c4a